Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NNMT | P40261 | 2/20 | 0.44 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
| ▸ | DAO | P14920 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.38 |
| ▸ | PI4KA | P42356 | 1/20 | 0.38 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.38 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.38 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12599375 | 0.84 | KDM1A (0.42) | NNMTCYP2A6DAOKDM1AMAOA | |
| SCHEMBL18387804 | 0.79 | KDM1A (0.40) | NNMTCYP2A6DAOKDM1AMAOA | |
| SCHEMBL18387803 | 0.75 | KDM1A (0.37) | NNMTCYP2A6DAOKDM1AMAOA | |
| SCHEMBL441300 | 0.75 | LOXL2 (0.60) | CHRM1 | |
| SCHEMBL1146238 | 0.74 | LOXL2 (0.53) | NNMTCYP2A6MKNK1MKNK2DAO | |
| SCHEMBL29658888 | 0.74 | LOXL2 (0.53) | NNMTCYP2A6MKNK1MKNK2DAO | |
| SCHEMBL29491632 | 0.74 | NNMT (0.47) | NNMTCYP2A6MKNK1MKNK2DAO | |
| SCHEMBL5547238 | 0.74 | LOXL2 (0.53) | NNMTCYP2A6MKNK1MKNK2DAO | |
| SCHEMBL247713 | 0.74 | NNMT (0.47) | NNMTCYP2A6MKNK1MKNK2DAO | |
| Ammonia Solution, Strong SCHEMBL6061986 | 0.73 | LOXL2 (0.52) | NNMTCYP2A6MKNK1MKNK2DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2097384-B1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2012-09-12 | — | — | EP | disclosed |
| CN-101646654-B | Indazolyl sulfonamide derivatives useful as glucocorticoid modulators | ASTRAZENECA AB | 2012-03-28 | — | — | CN | disclosed |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | BERGER MARKUS (DE) | 2012-03-15 | — | — | US | disclosed |
| EP-2097384-A1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | AstraZeneca AB (SE) | 2009-09-09 | — | — | EP | disclosed |
| US-20080207721-A1 | Chemical compounds | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-08-28 | — | — | US | disclosed |
| WO-2008063116-A1 | INDOZALYL SULPHONAMIDE DERIVATIVES USEFUL AS GLUCOCORTICOID MODULATORS | ASTRAZENECA AB (SE) | 2008-05-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207721-A1 | Chemical compounds | NR3C1, NR3C2, MC2R | NNMT 3480/4885CYP2A6 178/4885MKNK1 2011/4885 |
| US-20120065173-A1 | CHEMICAL COMPOUNDS | NR3C1, NR3C2, MC2R | NNMT 3489/4885CYP2A6 183/4885MKNK1 1971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.